We are Alzheimer Europe
Alzheimer Europe is the umbrella organisation of 35 national Alzheimer's associations from 32 European countries.
Our mission is to change perceptions, policy and practice in order to improve the lives of people affected by dementia. We are a non-profit non-governmental organisation (NGO) and will achieve our mission by providing a voice to people with dementia and their carers, making dementia a European priority, changing perceptions and combating stigma, raising awareness of brain health and prevention, strengthening the European dementia movement and supporting dementia research.
Our work
Recent tweets
Missed our #AELunchDebate on the role of artificial intelligence and big data in #dementia research? You can read some of the key topics that were discussed during the debate here.
Missed our #AELunchDebate on the role of artificial intelligence and big data in dementia research? Find out some of the key topics that were discussed here:
@KevinQuaid3 Thank you and everyone in the #EWGPWD for everything you do! Your vital work is much appreciated by us all.
Pleased to announce the next European Working Group of People with Dementia #EWGPWD for 2022-2024. New group's mandate starts after our upcoming conference #32AEC. Huge thank you to outgoing 2020-2022 group members for their important work!
https://t.co/67M9rAMnia
Members of the @eufingers and @lethe_project Advisory Boards participates in a consultation on the CAIDE Risk Score
https://t.co/8D8Isn0GJj
Great to see our sponsors and member organisations at our recent Company Round Table meeting! We heard about recent research and policy developments, with updates on #dementia prevalence and the new EU pharmaceutical legislation. Thanks for joining us!
https://t.co/RAXMQb4Au5
Post-hoc analysis of results from the TRAILBLAZER-ALZ study of #donanemab identifies potential associations between amyloid lowering, tau pathology, and clinical outcomes @JAMANeuro #AEScienceWatch
https://t.co/GC3izEDrkt
Researchers from @kaistpr have developed a new agent for #Alzheimer’s disease that may overcome the side effects of conventional antibody therapy. Findings were published in @NatureMedicine
https://t.co/DpIxKVtLjh
